Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA’s Diabetes Guidance On CV Risk Will Get First Test With Pending NDAs

Executive Summary

FDA's flexibility in applying its new guidance for cardiovascular safety of diabetes drugs will be tested in coming months as it reviews a handful of pending NDAs and enters into discussions about other drugs in late stages of development

Related Content

For Some, Oral Insulin’s Allure Persists Despite Hurdles
Clinical Safety Assessments Need Formal Protocols, FDA Says; Guidance On "Synthesis" Possible
Glycemic Control Not Enough For New Diabetes Drugs, Roche Exec Says
REMS For Obesity Drugs May Need More Specifics After Qnexa Advisory Panel
Diabetes Drug Developers Urged To Study Higher Risk Patients By FDA Panel
Type 2 Diabetes Developers Take Heart: New Safety Hurdle Is Surmountable
Roche Forges Ahead With Taspoglutide Despite Other GLP-1 Cancer Signal
VCs Think Twice About Type 2 Diabetes Investments
Bristol Readies Saxagliptin Launch In Anticipation Of FDA Approval
MannKind Breathes Easier After FDA Diabetes Safety Guidance



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts